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Abstract
Although camptothecin (CPT) has been reported to
induce apoptosis in various cancer cells, the molec-
ular details of this regulation remain largely unknown.
In this study, we demonstrate that BH3-only protein
Noxa is upregulated during CPT-induced apoptosis,
which is independent of p53. In addition, we show
that phosphatidylinositol 3-kinase (PI3K)/Akt signal-
ing pathway is responsible for Noxa’s induction. Lu-
ciferase assay and cAMP response element binding
protein (CREB) knockdown experiments further dem-
onstrate that CREB is involved in the transcriptional
upregulation of Noxa. Moreover, blocking Noxa ex-
pression using specific small interfering ribonucleic
acid (siRNA) significantly reduces the apoptosis in re-
sponse to CPT, indicating that Noxa is an essential
mediator for CPT-induced apoptosis. Interestingly, anti-
apoptotic Mcl-1 was also upregulated through PI3K/Akt
signaling pathway upon CPT treatment. Using immu-
noprecipitation assay, Noxa was found to interact with
Mcl-1 in the presence or absence of CPT. Knockdown
of Mcl-1 expression by short hairpin ribonucleic acid
(shRNA) was shown to potentiate CPT-induced apop-
tosis. Consistently, ectopic overexpression of Mcl-1
rescued cells from apoptosis induced by CPT. Cells
coexpressing Noxa and Mcl-1 at different ratio corre-
lates well with the extent of apoptosis, suggesting that
the balance between Noxa and Mcl-1 may determine the
susceptibility of HeLa cells to CPT-induced apoptosis.
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Introduction
Apoptosis, also termed as programmed cell death, is an
evolutionarily conserved and genetically controlled cellular
suicide mechanism [1]. It plays a pivotal role in the regula-
tion of tissue development and homeostasis [2]. Growing
evidences have shown that failure or defects in the apopto-
tic pathway may contribute to the generation of drug resis-
tance [3]. The signaling events leading to apoptosis can be
divided into two distinct pathways, i.e., extrinsic and intrinsic
cell death pathways [4]. In the intrinsic pathway, mitochon-
dria play a central role in the integration and execution of
variety of apoptotic signals. Death signals lead to changes in
mitochondrial membrane permeability and the subsequent
release of proapoptotic proteins such as cytochrome c [5]. Re-
lease of cytochrome c results in the Apaf-1–mediated ac-
tivation of initiator caspase-9, which, in turn, activates other
effector caspases [6]. Among the components that regulate
the intrinsic pathway of apoptosis, Bcl-2 family proteins have
been reported to play a major role [7]. By forming heterodimeric
complexes at the mitochondria, Bcl-2 family members promote
or suppress apoptosis.
Bcl-2 family of proteins can be divided into three groups, i.e.,
multidomain antiapoptotic proteins (such as Bcl-2, Bcl-xL, and
Mcl-1), multidomain proapoptotic proteins (such as Bax, BAK,
and Bok), and BH3-only proapoptotic members (e.g., Puma,
Noxa, Bid, and Bim) [8]. The proapoptotic BH3-only proteins are
the most apical regulators of apoptosis induction. In response to
apoptotic stimuli, they will be engaged in transcriptional regu-
lations or posttranslational modifications [9], ultimately leading
to the activation of Bax and BAK. It has been reported that
deficiency in Bax and BAK renders cells resistant to apopto-
sis induced by various apoptotic stimuli [10–12], indicating that
BH3-only proteins function upstream of Bax and BAK.
Despite the extensive interactions between Bcl-2 family pro-
teins, their respective interaction appears to be selective and
specific. For instance, Bim and Puma can bind all of the muti-
domain antiapoptotic Bcl-2 family members, whereas Noxa
only binds to Mcl-1, but not Bcl-2 and Bcl-xL [13,14]. On the
contrary, Bad interacts with Bcl-2 and Bcl-xL, but not with Mcl-1
[13,15]. Strikingly, Bid and Bim are able to directly interact
with BAK and Bax, resulting in their oligomerization [16–18].
Recent data showed that, in healthy cells, BAK is functionally
inactive due to the formation of BAK–Mcl-1 complex; however,
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accumulation of Noxa leads to the release of BAK from
BAK–Mcl-1 complex and its subsequent activation [19,20].
In light of these evidences, it is evident that Bcl-2 family
members regulate apoptosis using two distinct models. In
the first model, Bid-like BH3-only proteins activate apoptosis
through direct interaction with Bax and BAK. The second is
that Noxa-like BH3-only proteins sensitize apoptosis by bind-
ing to and neutralizing the antiapoptotic Bcl-2 family proteins,
thereby releasing Bax and BAK.
Camptothecin (CPT) is a specific inhibitor of topoisomer-
ase I and can bind to and stabilize the normally transient
DNA–topoisomerase I cleavage complex to collide with
the DNA replication fork [21,22], resulting in an irreversible
double-strand break and eventually cell death [23,24]. CPT
has been reported to induce apoptosis in various cancer
cells and some of these cells are lacking in functional p53
[25–28], implying that CPT can induce apoptosis in a p53-
independent manner.
Although some features characteristic of apoptosis in-
duction by CPT have been already described, the underly-
ing molecular mechanism remains to be fully elucidated. In
this study, we showed that CPT was able to transcriptionally
upregulate Noxa in a p53-independent manner, in which
phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway
is involved. In addition, we demonstrated that transcription
factor cAMP response element binding protein (CREB) was
responsible for the Noxa’s induction. More importantly, Noxa
was shown to be an essential mediator for CPT-induced
and caspase-9– involved apoptosis. Unexpectedly, we found
that antiapoptotic Mcl-1 was also upregulated through PI3K/
Akt signaling pathway upon CPT treatment. We demon-
strated that Noxa was able to interact with Mcl-1 both in
CPT-treated and -untreated cells. Finally, we hypothesized
that the ratio of Noxa to Mcl-1 may regulate the shift in the
balance of cell fate toward cell death versus survival upon
CPT treatment.
Materials and Methods
Reagents and Antibodies
The following antibodies were used in this study: anti–
Mcl-1 and anti-Bax (Santa Cruz Biotechnology, Santa Cruz,
CA); anti–caspase-9 (Immunotech, Marseilles, France); anti–
green fluorescent protein (GFP) (BD Biosciences, Palo Alto,
CA); anti-Flag (Sigma, St Louis, MO); anti-Noxa (Imgenex,
San Diego, CA); anti-Puma, anti-AKT, anti-pAKT (S473), and
anti-CREB (Cell Signaling Technology, Danvers, MA); and
anti–b-actin (Abcam, Cambridge, United Kingdom). Cyclohex-
imide (CHX), camptothecin (CPT), geneticin (G418), doxoru-
bicin, and Hoechst 33342 were purchased from Sigma and
LY294002 was purchased from Calbiochem (La Jolla, CA).
MitoTracker Red CMXRos was purchased from Molecular
Probes (Carlsbad, CA).
Cell Culture and Transfection
Cell lines HeLa and H1299 were cultured in Dulbecco’s
modified Eagle’s medium containing 10% heat-inactivated
fetal bovine serum, 1  nonessential amino acid, 100 mg/ml
penicillin, 1  MEM sodium pyruvate, 100 mg/ml streptomycin
(Invitrogen, Carlsbad, CA) at 37jC under an atmosphere of
5% CO2 in air. Transfection of cells with various mammalian
expression constructs by Lipofectamine 2000 (Invitrogen)
was according to the methods provided by the manufacturer.
To establish HeLa cell line stably expressing Mcl-1 or con-
trol short hairpin ribonucleic acid (shRNA), Mcl-1 or control
shRNA expression plasmid (kindly provided by Dr. Gregory
J. Gores) was individually transfected into HeLa cells. Forty-
eight hours after transfection, clones were selected in culture
medium containing 1 mg/ml geneticin (G418) for 3 weeks.
The positive clones were further confirmed by Western
blot analysis.
RNA Interference (RNAi)
In our study, knock out RNAi system (Clontech Laboratories,
Mountain View, CA) was used to knock down CREB protein
level. Nineteen–base pair target sequence for CREB was 5V–
TAC AGC TGG CTA ACA ATG G–3V. To knock down the endo-
genous level of Noxa, small interfering ribonucleic acid (siRNA)
for Noxa (sc-37305; Santa Cruz Biotechnology) was transfected
into HeLa cells according to themanufacturer’s instructions. The
effect of RNAi on CREB or Noxa protein level was measured by
Western blot analysis after 48 hours of transfection.
Western Blot Analysis and Immunoprecipitation
Western blot analyses were performed mainly as de-
scribed by Mei et al. [29] with following modifications. After
incubating with first and second antibodies, blots were de-
veloped by electrochemical luminescence (Lumi-Phos WB;
Pierce, Rockford, IL). For immunoprecipitation, HeLa cells
were lysed in a NP-40–based lysis buffer (0.2% NP-40,
150 mM NaCl, 20 mM Hepes, pH 7.5, 2 mM EDTA, and
1.5 mM MgCl2) supplemented with protease inhibitor cock-
tail and 20 mg/ml MG132 for 1 hour on ice. Cytosolic lysate
was incubated with anti–Mcl-1 antibody bound to Protein
A/G–Sepharose. After incubating at 4jC overnight, the im-
munoprecipitates were washed five times in lysis buffer and
proteins were recovered by boiling the beads in sodium
dodecyl sulfate sample buffer and analyzed by Western blot
analysis using anti-Noxa antibody.
Protein Stability Assay
After incubating with or without CPT (10 mM) for 9 hours,
HeLa cells were further treated with 25 mg/ml CHX for in-
dicated periods of time and were then harvested and ana-
lyzed by Western blot analysis as described above.
Reporter Plasmids and Luciferase Assay
The reporter plasmids used in this study (pGL3–Noxa–wt,
pGL3–Noxa–mtCRE, and pGL3–Noxa–mtP53) were kindly
provided by Dr. C. Lallemand. To analyze the promoter activity
of these reporter genes, H1299 cells were transiently trans-
fected with these plasmids. Renilla luciferase reporter plas-
mid was included as an internal control. Firefly and Renilla
luciferase activity were assayed (Dual-Luciferase Reporter
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Assay System; Promega Corporation, WI) according to the
manufacturer’s instructions. Tcf/Lef reporter activities were
normalized relative to Renilla luciferase activities and pre-
sented as means (± SD) of three independent experiments.
Semi-Quantitative Reverse Transcription–Polymerase
Chain Reaction (RT-PCR)
For semi-quantitative RT-PCR, HeLa cells were treated ei-
ther with CPT (10 mM) alone or in combination with LY294002
(40 mM) for 12 hours. Total RNA was isolated using SV Total
RNA Isolation System (Promega Corporation) and 0.1 mg of
RNA of each sample was used as template. RT-PCR was
performed by TaKaRa One-step RNA PCR Kit (TaKaRa Bio
Inc., Otsu, Japan) using the following specific primer pairs:
Noxa, 5V–ATG CCT GGG AAG AAG GCG CGC–3V and 5V–
TCA GGT TCC TGA GCA GAA GAG–3V; b-actin, 5V–GAC
CTG ACT GAC TAC CTC ATG AAG AT–3V and 5V–GTC ACA
CTT CAT GAT GGA GTT AAG G–3V.
Apoptosis Assay
Apoptosis assay was performed mainly as described pre-
viously [30]. Briefly, cells were treated with CPT (10 mM) or in
combination with other reagents for the indicated periods of
time. The viability of cells was measured by counting the
number of apoptotic cells characteristic of aberrant nuclei
staining by Hoechst 33342, and was normalized to the num-
ber of total cells. Data were presented as means (±SD) of
three independent experiments.
Results
CPT Induces Noxa Expression
in a p53-Independent Manner
CPT, an inhibitor of topoisomerase I, is known to induce
apoptosis in various cancer cells [25–28]. In accordance
with these reports, we also found that CPT was able to in-
duce apoptosis in HeLa cells. After 24 hours of exposure
to CPT, HeLa cells were shown to have approximately
40% apoptotic cell death (Figure 1A, upper part). To evalu-
ate whether caspase-9 activation is involved during CPT-
induced apoptosis, Western blot analysis was performed.
As shown in Figure 1A, caspase-9 activation became de-
tectable after 3 hours of CPT treatment, indicating that mito-
chondria apoptotic pathway is truly involved in CPT-induced
apoptosis. To further investigate the molecular mechanism
underlying CPT-induced apoptosis, we compared the effect
of CPT on the expression of three proapoptotic Bcl-2 family
members, namely Noxa, Puma, and Bax. As shown in Fig-
ure 1B, Noxa was significantly upregulated and its induction
was detectable as early as 6 hours following CPT treatment.
In contrast, neither Puma nor Bax showed any induction
upon CPT treatment, suggesting that Noxa is implicated in
playing a specific role during CPT induced apoptosis. Be-
cause p53 was previously shown to be upregulated by CPT
[31] and Noxa is a direct p53 target gene [19], we sought to
determine whether p53 was required for CPT-dependent
induction of Noxa. The effect of CPT on Noxa induction in
p53-null H1299 cells has been examined. As shown in Fig-
ure 1C, the kinetics of Noxa upregulation by CPT in H1299
cells was similar to that in HeLa cells. Thus, we conclude that
Noxa is upregulated by CPT in a p53-independent manner.
PI3K/Akt Signaling Pathway is Responsible
for CPT-Induced Noxa Induction
PI3K/Akt pathway has been shown to be activated by
various growth factors and play a critical role in cell survival
[32,33]. More specifically, previous data indicated that two
types of apoptotic stimuli, i.e., staurosporine and etoposide,
were capable of activating the PI3K/Akt pathway [34], which
then stimulates us to inquire whether this signaling path-
way can also be activated by CPT. To address this issue,
we examined the PI3K-dependent activation of Akt phos-
phorylation after CPT treatment. HeLa cells were treated
with CPT for the indicated periods of time and Akt phosphor-
ylation on serine 473 was used as a read-out of PI3K activ-
ity [35]. As shown in Figure 2A, CPT-induced pAkt was
increased in a time-dependent manner, peaking at 9 hours.
To further determine that the activation of PI3K/Akt pathway
indeed contributes to Noxa induction upon CPT treatment,
HeLa cells were treated either with CPT alone or in combi-
nation with LY294002, a specific PI3K inhibitor, for 12 hours
(Figure 2B). As was expected, Noxa was significantly in-
duced by CPT, however, addition of LY294002 markedly ab-
rogated CPT-induced Noxa upregulation, indicating Noxa
induction is closely correlated with PI3K activity (lane 3 vs
2). Together, these data suggest that PI3K/Akt signaling
pathway is responsible for CPT-induced Noxa upregulation.
Noxa is Transcriptionally Upregulated By CPT Treatment,
in Which CREB is Involved
Because Noxa is an unstable protein and is subject to
proteasome-mediated protein degradation [36–38], upregu-
lated level of Noxa induced by CPT could be attributed to
either less protein degradation or more RNA transcription. To
distinguish between these two possibilities, the half-life of
Noxa was compared in the presence and absence of CPT.
As shown in Figure 3A, although the protein level of Noxa
after CHX treatment was higher in the presence than in the
absence of CPT, two patterns of decrease in Noxa in the
presence and in the absence of CHX displayed in parallel as
shown in Figure 3 (upper panels). In addition, total RNA was
extracted from HeLa cells treated either with CPT alone or
in combination with LY294002 and a semi-quantitative RT-
PCR was performed. As shown in Figure 3B, Noxa mRNA
level was increased upon CPT treatment (lane 2 vs lane 1);
however, when LY294002 was additionally added, Noxa
level was significantly inhibited (lane 3 vs lane 2), implying
that Noxa is transcriptionally regulated by CPT through the
PI3K/Akt signaling pathway.
Transcription factor CREB was known as a regulatory
target for the Akt kinase [39]. Recently, it has been shown
that CREB is involved in the induction of Noxa by single-
stranded RNA viruses by binding to cAMP-responsive ele-
ment (CRE) binding site within the Noxa promoter [40]. To
address whether CREB is also involved in CPT-induced
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Noxa induction, a reporter assay was performed. HeLa cells
were individually transfected with pGL3–Noxa–wt, pGL3–
Noxa–mtCRE, or pGL3–Noxa–mtp53. Twenty-four hours
posttransfection, cells were treated with or without CPT for
another 15 hours. As shown in Figure 3C-b, CPTwas shown
to activate the wt-Noxa promoter, whereas mutation in CRE
binding site notably diminished the Noxa promoter activity,
suggesting that CRE binding site indeed plays an essential
role in the stimulation of Noxa gene transcription by CPT
treatment. In contrast, mutation in the p53 binding site within
the Noxa promoter has little, if any, effect on the activa-
tion of the promoter by CPT, which further supports our
previous conclusion that CPT-induced Noxa upregulation
is independent of p53. Next, we knocked down the expres-
sion of the CREB to further confirm its role in CPT-induced
Noxa upregulation. As shown in Figure 3D, the induction of
Noxa by CPTwas proportionally reduced in accordance with
knockdown of CREB expression using CREB RNAi (lane 3,
top panel vs lane 3, middle panel). These results demon-
strate that CREB is involved in the transcriptional upregula-
tion of Noxa induced by CPT.
Noxa is Essential, But Not the Sole Determinant for
CPT-Induced Apoptosis
Given that Noxa is upregulated by CPT, we further in-
vestigated whether the induction of Noxa contributes to CPT-
induced apoptosis. HeLa cells were transfected with control
or Noxa-specific siRNA, and at 48 hours posttransfection,
Figure 1. Noxa is upregulated in CPT-induced apoptosis. (A) HeLa cells were treated with 10 M CPT for the indicated periods of time (0, 1, 3, 6, 9, 12, and 24
hours). The viability of cells was measured by counting apoptotic cells characteristic of aberrant nuclei staining by Hoechst 33342 and was normalized to the
number of total cells. Data were presented as means (± SD) of three independent experiments. Cell lysate harvested at different time points was used to assess
the activation of caspase-9 with anti – caspase-9 antibody by Western blot analysis. Actin was used as loading control. (B) After treatment with 10 M CPT for the
indicated periods of time (0, 1, 3, 6, 9, 12, and 24 hours), HeLa cells were harvested and analyzed by Western blot analysis using anti-Noxa, anti-Bax, and anti-
Puma antibody, respectively. (C) After incubating for the indicated periods of time in the presence of CPT (10 M), H1299 cells were harvested and Western blot
analysis were conducted using anti-Noxa antibody.
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cells were treated with CPT for another 12 and 24 hours.
As shown in Figure 4A, protein levels of Noxa were obvi-
ously lower in Noxa siRNA–transfected cells than in control
siRNA–transfected cells (lower part, top panel, lane 2, 4 vs
lane 1, 3). CPT-induced apoptotic cell death resulting from
Noxa siRNA–transfected cells was lower than that from con-
trol siRNA–transfected cells (6% vs 21% at 12 hours and
12% vs 38% at 24 hours), suggesting that Noxa truly con-
tributes to the CPT-induced cell death. Notably, a marked
cleavage of caspase-9, as a marker of apoptosis, occurred
more prominently in control siRNA–transfected cells than
in Noxa siRNA–transfected cells (lower part, middle panel,
lane 1, 3 vs lane 2, 4), further indicating that CPT-induced
and Noxa-mediated cell death is through an intrinsic apopto-
tic pathway.
To examine whether additional protein(s) is (are) involved
in regulating CPT-induced apoptosis, HeLa cells were treated
with CPT in the absence or presence of CHX. The extent of
cell death was measured by direct counting of cells with apop-
totic nuclear morphology 12 hours after treatment. Caspase-9
activation was also assessed in CHX-treated or -untreated
cells by its proteolytical processing. As shown in Figure 4B-a,
in the absence of CHX, CPT treatment resulted in activation
of caspase-9 followed by manifestation of apoptotic morphol-
ogy inf 22% of cells observed (lane 2 vs lane 1). However,
inhibition of de nova protein synthesis by CHX significantly
augmented caspase-9 activation and increased the CPT-
induced apoptotic cell death from 22% to nearly 70%. We
noticed that in the presence of CHX, the induction of Noxa by
CPT was completely blocked and Noxa became hardly de-
tectable (lower part, top panel, lane 3 vs lane 2). This data
implies that CPT-induced apoptosis can take place when
Noxa fell to an undetectable level and, logically, extra pro-
tein(s) (most likely antiapoptotic proteins) should be involved
in this apoptotic induction. To further verify this assumption,
HeLa cells were treated with CPT in the absence or presence
of LY294002 that was shown to inhibit the Noxa expression
(Figure 2B). The activation of caspase-9 was measured
and apoptotic cell death was calculated 24 hours after treat-
ment. As shown in Figure 4B-b, CPT-induced Noxa induction
was almost completely inhibited by LY294002 (lower part,
top panel, lane 3 vs lane 2) and additional treatment with
LY294002 significantly increased CPT-induced apoptosis by
52% (upper part, lane 3 vs lane 2), which was inconsistent
with the previous reports [41,42]. These results further confirm
that Noxa alone cannot fully account for CPT-induced apop-
tosis and that determinant(s) other than Noxa should be also
regulated by the PI3K/Akt signaling pathway.
During performance of this study, we found that CPT up-
regulated the expression of Mcl-1, one of the antiapoptotic
Bcl-2 family proteins, but not Bcl-2 or Bcl-xL (data not shown).
As shown in Figure 4C-a (upper part), Mcl-1 was induced
by CPT in a time-dependent manner. In contrast, Mcl-1 was
downregulated upon doxorubicin treatment (Figure 4C-a,
lower part). To determine whether PI3K/Akt signaling pathway
is involved in the upregulation of Mcl-1 by CPT, HeLa cells
were treated either with CPT alone or in combination with
LY294002 for 12 hours before cell lysates were harvested
(CPT-untreated cells were used as a control). As a result,
addition of LY294002 resulted in a significant inhibition of
CPT-induced Mcl-1 upregulation (Figure 4C-b, lane 3 vs lane
2). Taken together, these results suggest that, in addition to
Noxa, Mcl-1 may be another determinant that is involved in
PI3K/Akt signaling in CPT-induced apoptosis.
Ratio of Noxa to Mcl-1 Regulates Cells’ Susceptibility
to CPT-Induced Apoptosis
Given that both proapoptotic Noxa and antiapoptotic
Mcl-1 are upregulated during CPT-induced apoptosis, it is
not unreasonable to suspect that the balance between Noxa
and Mcl-1 might be the underlying mechanism in regulat-
ing cell death/survival upon CPT treatment. To address this
issue, we sought whether there exists an interaction between
Noxa and Mcl-1 upon CPT treatment. HeLa cells were
treated with or without CPT for 12 hours. Cell lysates were
then incubated with either control antibody or anti–Mcl-1
antibody bound to Protein A/G–Sepharose. The immuno-
precipitates were recovered and subjected to Western blot
analysis using anti-Noxa antibody. As shown in Figure 5A,
endogenous Mcl-1 and Noxa indeed interacts with each
other both in the presence and in the absence of CPT. If
the hypothesis that balance between Noxa and Mcl-1 deter-
mines cell fate after CPT treatment was true, we would
expect that knockdown of Mcl-1 (or Noxa) would increase
(or decrease) the susceptibility to CPT-induced apoptosis. To
test this hypothesis, HeLa cells stably expressing control
or Mcl-1 shRNA was individually treated with CPT for 12 or
24 hours, and the cell viability was calculated by counting
apoptotic cells characteristic of aberrant nuclei. As shown in
Figure 5B, effective knockdown of Mcl-1 was observed
Figure 2. PI3K/Akt signaling pathway is involved in CPT-induced upregulation
of Noxa. (A) After treatment with CPT (10 M) for the indicated periods of time
(0, 1, 3, 6, 9, 12, and 24 hours), whole cell lysates were prepared and im-
munoblotted using anti-pAkt or anti-Akt antibody. (B) HeLa cells were treated
with CPT (10 M) or with CPT (10 M) and LY294002 (40 M) for 12 hours.
Cell lysates were then prepared and subjected to Western blot analysis using
indicated antibodies. Endogenous actin was used as loading control.
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Figure 3. CREB, but not p53, is responsible for the transcriptional upregulation of Noxa upon CPT treatment. (A) After incubation with or without CPT (10 M) for
9 hours, HeLa cells were further treated with CHX (20 g/ml) for indicated times (0, 0.5, 1, 2, and 3 hours) before cell extracts were collected. The protein levels of
Noxa at different time points were compared by Western blot analysis using anti-Noxa antibody and endogenous actin was used as loading control. (B) HeLa cells
were treated with CPT (10 M) alone or in combination with LY294002 (40 M) for 12 hours. Total RNA was extracted from each of these treated samples and the
equal amounts of RNA were used for amplification of Noxa cDNA fragment. -Actin was used as internal control. (C) a. Schematic representation of the Noxa
promoter luciferase reporter constructs used in this study. Mutated binding sites are indicated by shaded boxes. b. HeLa cells were transiently transfected with the
various reporter plasmids shown in (a). Renilla luciferase plasmid pRL-CMV was also introduced into transfected cells as internal control. Twenty-four hours after
transfection, cells were treated with or without CPT (10 M) for another 15 hours. Luciferase activity was measured and plotted after normalizing with respect to
Renilla luciferase activity (mean ± SD). (D) a. H1299 cells were individually transfected with either CREB or control shRNA expression plasmid. Forty-eight hours
after transfection, cells were treated with or without CPT (10 M) for 12 hours before cell lysates were prepared and subjected to Western blot analysis using
indicated antibodies. Endogenous actin was used as loading control. b. Scanning densitometry was performed for each band in the blot indicated in D-a and an
image analysis software (Scion Image; Scion, Frederick, MD) was used.
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Figure 4. Noxa alone cannot account for the CPT-induced apoptosis. (A) Knockdown of Noxa expression protects cells against CPT-induced apoptosis. HeLa cells
were transfected with control or Noxa-specific siRNA (sc-37305; Santa Cruz Biotechnology). At 48 hours posttransfection, cells were treated with CPT (10 M) for
another 12 or 24 hours. The viability of cells was measured by counting apoptotic cells characteristic of aberrant nuclei staining by Hoechst 33342 and was normalized
to the number of total cells. Data were presented as means (± SD) of three independent experiments. Cell lysates were also collected and subjected to Western blot
analysis using anti-Noxa and anti–caspase-9 antibodies. Endogenous actin was detected by anti-actin antibody as internal control. (B) HeLa cells were treated with
CPT (10 M) alone or in combination with either (a) CHX (20 g/ml) or (b) LY294002 (40 M) for indicated periods of time. The viability of cells was measured
according to the method described in (A). Noxa protein level and the activation of caspase-9 were assessed by Western blot analysis. (C) CPT-induced Mcl-1
upregulation is inhibited by LY294002. a. HeLa cells were treated with CPT (10 M) or doxorubicin (2 g/ml) for indicated periods of time (0, 1, 3, 6, 9, 12, and
24 hours) before cell lysates were prepared. Levels of Mcl-1 protein were assessed by Western blot analysis using anti –Mcl-1 antibody. Actin acted as a loading
control. b. HeLa cells were treated with CPT (10 M) or with CPT (10 M) plus LY294002 (40 M) for 12 hours. Cell lysates were then used for Western blot analysis
with anti –Mcl-1 antibody and endogenous actin was used as internal control.
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Figure 5. Balance between Noxa and Mcl-1 regulates cells’ susceptibility to CPT-induced apoptosis. (A) Interaction between endogenous Noxa and Mcl-1. HeLa cells
were treated with or without CPT (10 M) for 12 hours. Cell lysates were then incubated with control antibody or anti–Mcl-1 antibody bound to Protein A/G–
Sepharose. The immunoprecipitates were recovered in sodium dodecyl sulfate sample buffer and subjected to Western blot analysis using anti-Noxa antibody with
electrochemical luminescence-based detection. (B) Effect of Mcl-1 knockdown on the apoptosis induced by CPT. HeLa cells stably expressing control or Mcl-1 shRNA
were individually treated with CPT (10 M) for indicated periods of time. The viability of cells was measured by counting apoptotic cells characteristic of aberrant nuclei
staining by Hoechst 33342 and was normalized to the number of total cells. Data were presented as means (± SD) of three independent experiments. Cell lysates
were also harvested and subjected to Western blot analysis using indicated antibodies. Endogenous actin was used as internal control. (C) HeLa cells stably
expressing GFP or GFP–Mcl-1 were treated with CPT (10 M) or with CPT (10 M) plus LY294002 (40 M) for 24 hours. The viability of cells was measured
according to the method described in (B) andWestern blot analysis was performed to assess the activation of caspase-9 with anti –caspase-9 antibody. (D) HeLa cells
were transiently cotransfected with GFP–Noxa and Flag–Mcl-1 expression plasmids varying in different ratios as indicated. Twenty-four hours posttransfection, the
viability of cells was measured by directly counting GFP-positive apoptotic cells characteristic of aberrant nuclei staining by Hoechst 33342. Cell lysates were also
harvested and subjected to Western blot analysis using indicated antibodies.
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(lower part, top panel, lane 2, 4 vs lane 1, 3), and Mcl-1
knockdown resulted in amarked potentiation of CPT-induced
apoptotic cell death by 19% (upper part, lane 2 vs lane 1) and
17% (upper part, lane 4 vs lane 3) at 12 and 24 hours
respectively. The activation (cleavage) of caspase-9 was
correlated with the extent of apoptosis. Consistently, HeLa
cells stably expressing GFP–Mcl-1 showed significant re-
sistance to apoptosis induced either by CPT alone or CPT
and LY294002 compared with cells stably expressing GFP
only (Figure 5C, upper part). A direct correlation was also
observed between the cleavage (activation) of caspase-9
and the extent of apoptosis (lower part, top panel). As al-
ready described in Figure 4A, knockdown of Noxa is expect-
edly to reduce the apoptosis induced by CPT. Based on
these data, it indicates that the ratio of Noxa to Mcl-1 might
be involved in the regulation of cellular apoptotic response
to CPT.
To further quantitatively validate this hypothesis, HeLa
cells were transiently cotransfected with GFP–Noxa and
Flag–Mcl-1 expression plasmids varying in different ratios.
As shown in Figure 5D, decreasing the Noxa–to–Mcl-1 ratio
from 400/100 to 100/400 concurrently reduces the apoptosis
induced by CPT (upper part). Although the increased Mcl-1
level was clearly seen on the blot, the reduction of Noxa,
however, is less obvious, which could be because, as the
level of Noxa increases, more extensive cell death will occur.
This result suggests that the ratio of Noxa to Mcl-1 may in-
deed regulate cell apoptosis decision to undergo apoptosis
versus survival upon CPT treatment.
Discussion
Bcl-2 family proteins have been implicated in playing a major
role in regulating the apoptosis pathway [7], and proapopto-
tic BH3-only proteins are the most apical regulators of apop-
tosis induction. Noxa, belonging to proapoptotic BH3-only
Bcl-2 family, was reported to be upregulated by phorbol
ester, p53, E2F1, hypoxia-inducible factor (HIF)-1a, UV ra-
diation, and other DNA-damaging agents such as etoposide
and adriamycin [19,43–48]. In this study, we demonstrated
that CPT was able to induce Noxa expression in a p53-
independent manner, despite that p53 was shown to be up-
regulated and activated by CPT [31]. Further results from
Noxa knockdown experiments suggest that Noxa plays an
important role in CPT-induced apoptosis.
PI3K/Akt pathway was shown to be activated by various
growth factors and play a critical role in cell survival [32,33].
Moreover, recent study has showed that PI3K/Akt pathway
can also be activated by staurosporine and etoposide [34].
Similarly, we have demonstrated that CPT was capable of
activating PI3K/Akt pathway, which was involved in signaling
Noxa induction. Although Noxa was reported to be an un-
stable protein [36–38], we have not yet found that CPT can
alter Noxa protein stability. Nevertheless, we showed that
Noxa was upregulated by CPT at the transcriptional level, in
which CREB is involved. This result is not unconceivable,
because CREB has been shown to be a regulatory target
for the Akt kinase [39] and, more recently, it was shown that
CREB plays a vital role in the induction of Noxa by single-
strand RNA viruses [40].
PI3K/Akt signaling pathway was known to be involved in
the upregulation of Mcl-1 by interleukin-3 [49]. In this report,
we demonstrated that, in addition to Noxa, Mcl-1 was also
upregulated by CPT involving PI3K/Akt signaling pathway. It
has already been reported that Mcl-1 protein level was up-
regulated in response to DNA-damaging agents other than
CPT [50] and, therefore, our observation that CPT mediated
Mcl-1 induction is not totally exceptional. However, upregu-
lation of antiapoptotic Mcl-1 in response to apoptotic stimulus
CPT may imply two causes. Firstly, CPT-induced Mcl-1 up-
regulation may represent cell’s instinctive survival response
to the death stimuli, or alternatively, induction of Mcl-1 may
stand for the molecular basis underlying the mechanism of
acquired resistance to CPT.
Given that both antiapoptotic protein Mcl-1 and proapop-
totic protein Noxa are upregulated by CPT and, moreover,
Noxa and Mcl-1 were able to interact with each other not only
in CPT-untreated cells but also in CPT-treated cells, we as-
sume that there might be a balance between Noxa and Mcl-1
to affect CPT-induced apoptosis. Knockdown of Mcl-1 is able
to significantly potentiate CPT-induced apoptosis, whereas
ectopic expression of Mcl-1 is capable of rescuing cells from
apoptosis induced by CPT. Cells coexpressing ectopic Noxa
and Mcl-1 at desired ratios result in an expected extent of
Figure 6. Hypothetical model of Noxa and Mcl-1 in the regulation of CPT-induced apoptosis. CPT activates PI3K/Akt signaling pathway, which, in turn, induces
upregulation of both Noxa and Mcl-1. Although the upregulation of Noxa through transcriptional factor CREB has been elucidated in this study, the transcription
factor responsible for CPT-induced Mcl-1 has not yet been identified. Nonetheless, based on the findings that Noxa can interact with Mcl-1 in the presence of CPT,
Noxa/Mcl-1 balance model may be borrowed to explain the susceptibility of cells to CPT-induced apoptosis: when the concentration of proapoptotic protein Noxa
exceeds that of antiapoptotic protein Mcl-1, CPT-induced apoptosis occurs (˛); however, when Mcl-1 takes the upper hand, more free Mcl-1 will ultimately lead to
CPT resistance (ˇ).
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apoptosis. These results indicate that the Noxa/Mcl-1 bal-
ance regulates cells’ susceptibility to CPT-induced apopto-
sis. Alves et al. proposed recently that the Noxa/Mcl-1 axis
plays an important role in glucose limitation–mediated apop-
tosis [51], which further supports our above conclusion. More
importantly, data revealed by this study may provide useful
information for clinical practice: combination treatment with
CPT and Mcl-1 interfering might be therapeutically more ef-
fective and beneficial compared to monotherapy with either
single agent in cancer chemotherapy. In conclusion, we pro-
pose a hypothetical model of Noxa and Mcl-1 in the regula-
tion of CPT-induced apoptosis as shown in Figure 6.
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